Compară metode

	Criteriile de diagnostic Roma IV pentru sindromul de intestin iritabil	Indexul Cardinal al Simptomelor Gastroparezei	Scala de Calitate a Vieții Legată de Sănătate în BRGE
Domeniu	Gastroenterologie	Gastroenterologie	Gastroenterologie
Familie	Process / pipeline	Process / pipeline	Process / pipeline
Anul apariției	2016	2003	1996
Autorul original	Rome Foundation (multinational expert consensus)	Revicki, D. A., Rentz, A. M., Dubois, D., et al.	Velanovich, V., Zhang, Y., Hollis, J. B., et al.
Tip	Diagnostic Criteria	Self-report	Self-report
Sursa seminală	Mearin, F., Lacy, B. E., Chang, L., et al. (2016). Bowel disorders. Gastroenterology. Published online June 2016 by the Rome Foundation.	Revicki, D. A., Rentz, A. M., Dubois, D., Kahrilas, P., Stanghellini, V., Talley, N. J., & Tack, J. (2003). Development and validation of a patient-assessed gastroparesis symptom severity index. Alimentary Pharmacology & Therapeutics, 18(1), 141–150.	Velanovich, V., Zhang, Y., Hollis, J. B., Feldman, M. I., Sampliner, R., Guan, W., & Escamilla, C. (1996). Presenting symptoms and outcome measures in reflux esophagitis. Digestive Diseases and Sciences, 41(10), 1865–1873.
Denumiri alternative	Rome IV IBS, Rome Criteria	GCSI	GERD-HRQL, GERD-HRQoL
Înrudite	4	4	4
Rezumat	The Rome IV criteria are the internationally accepted diagnostic standard for irritable bowel syndrome (IBS), published in 2016 by the Rome Foundation. These criteria define IBS as recurrent abdominal pain (≥1 day per week for ≥3 months) associated with altered bowel habits, without structural or biochemical abnormalities. IBS is subtyped into four patterns—IBS-constipation predominant (IBS-C), IBS-diarrhea predominant (IBS-D), IBS-mixed (IBS-M), and IBS-unclassified (IBS-U)—based on stool consistency patterns.	The Gastroparesis Cardinal Symptom Index (GCSI) is a validated, patient-reported outcome measure specifically designed to assess symptom severity in gastroparesis. Developed by Revicki and colleagues in 2003, the GCSI captures the three cardinal symptom clusters of gastroparesis: nausea and vomiting, postprandial fullness, and early satiety, plus bloating and stomach distension. The 9-item questionnaire is responsive to treatment changes and is increasingly used in clinical trials and practice to monitor gastroparesis progression and therapy response.	The GERD Health-Related Quality of Life Scale (GERD-HRQL) is a concise, validated patient-reported outcome measure for assessing the symptomatic and functional impact of gastroesophageal reflux disease (GERD). Developed by Velanovich and colleagues in 1996, the 9-item GERD-HRQL measures heartburn frequency and severity, regurgitation, and impact on sleep and medication use. The scale is highly responsive to proton pump inhibitor (PPI) therapy and is widely used in GERD trials and clinical practice.